Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Status:
Completed
Trial end date:
2020-09-09
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the effectiveness and safety of the medicine Ameluz®
(5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic
therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).